Calquence (acalabrutinib)

June 18, 2019

Forty Seven, Acerta Collaborate to Test Triple Combo Therapy on DLBCL Patients

News

Forty Seven and Acerta Pharma are collaborating to test a triple combination of the investigational 5F9 plus Rituxan (rituximab) and Calquence (acalabrutinib) in patients with diffuse large B-cell lymphoma (DLBCL). The partnership builds on ... Read more

January 4, 2019

Calquence Shows Durable Responses in Untreated CLL/SLL Patients in Phase 1/2 Trial

News

Calquence (acalabrutinib), given as a first-line treatment to patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), showed an acceptable safety profile and reduced tumor burden in 97 percent of patients in a Phase ... Read more